SCIENTIFIC WORK

1. Microbiological characteristic of the experimental use of “Autobiotic” on the model of antibiotic – induced dysbiosis in old rats / T. Ivakhniuk, O. Makarenko, Yu. Ivakhniuk, O. Molozhava // Modern Science –Moderní věda : Prague, Czech Republic. – 2018. – № 6. – Р. 107-113.

2. In vitro test-research of the indigenous intestinal microflora of the patients with Alzheimer disease / T. Ivakhniuk, Yu. Ivakhniuk, O. Makarenko, O. Molozhva, R. Dovgan // Modern Science –Moderní věda : Prague, Czech Republic. – 2019. – № 4. – Р. 136-142.

3. The role of PIK3CA mutations in the development of breast cancer (a literature review) / A.O. Pryvalova, I.O. Vynnychenko, V.Yu. Harbuzova, O.I. Vynnychenko, Yu.V. Moskalenko // Zaporozhye medical journal. – 2020. – V. 22, №4(121). – С. 554-560. https://doi.org/10.14739/2310-1210.2020.4.208402

4. Kuzenko O, Kuzenko Ye., Demin Yu. Enterosgel role in neurodegenerative changes in the retina rats under the influence of Cr (VI) – induced retinopathy by study morphological changes in dynamic. ScienceRise:Medical Science. 2021; 1(40): 14-20

5. Kuzenko OV, Kuzenko EV, Dyomin Yu.A. Investigation of the protective properties of methyl silicic acid hydrogel in relation to neurotoxicity induced by Cr (VI) in the optic nerve of rats. Ophthalmological journal. 2021; 1: 62-69.

6. Targeted therapy for non-small cell lung cancer focus on EGFR oncogenic mutation (literature review)/O. M. Smorodska, Yu. V. Moskalenko, I. O. Vynnychenko, O. I.[et al.] // Medicni perspektivi.- 2021 – Т. 26, № 2.- p. 8-11.

Scopus Author ID: https://www.scopus.com/authid/detail.uri?authorId=24781268000

h-index: 20

ORCID ID: https://orcid.org/0000-0002-2339-6509

1. The role of PIK3CA mutations in the development of breast cancer (a literature review) / A.O. Pryvalova, I.O. Vynnychenko, V.Yu. Harbuzova, O.I. Vynnychenko, Yu.V. Moskalenko // Zaporozhye medical journal. – 2020. – V. 22, №4(121). – С. 554-560. https://doi.org/10.14739/2310-1210.2020.4.208402
2. Targeted therapy for non-small cell lung cancer focus on EGFR oncogenic mutation (literature review)/O. M. Smorodska, Yu. V. Moskalenko, I. O. Vynnychenko, O. I.[et al.] // Medicni perspektivi.- 2021 – Т. 26, № 2.- p. 8-11.
3. Moskalenko Y, Kurochkin A, Vynnychenko I, Kravets O, Piddubnyi A, Moskalenko R, Potapov O. Toluidine blue for the detection of sentinel lymph nodes in patients with thyroid cancer. Contemp Oncol (Pozn). 2022;26(4):259-267. doi: 10.5114/wo.2022.124585. Epub 2022 Dec 30. PMID: 36816393; PMCID: PMC9933357.
4. Shah, M. A., Udrea, A. A., Bondarenko, I., Mansoor, W., Sánchez, R. G., Sarosiek, T., … & Ajani, J. A. (2022). Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. Cancers, 14(5), 1168.
5. Bedke, J., Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Waddell, T., … & Powles, T. (2022). Health-related quality of life analysis from KEYNOTE-426: pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma. European Urology, 82(4), 427-439.
6. de Castro Jr, G., Rizvi, N. A., Schmid, P., Syrigos, K., Martin, C., Yamamoto, N., … & NEPTUNE Investigators. (2023). NEPTUNE: phase 3 study of first-line Durvalumab plus tremelimumab in patients with metastatic NSCLC. Journal of Thoracic Oncology, 18(1), 106-119.
7. Psyrri, A., Fayette, J., Harrington, K., Gillison, M., Ahn, M. J., Takahashi, S., … & KESTREL Investigators. (2023). Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study. Annals of Oncology, 34(3), 262-274.
8. Ren, S., Feng, J., Ma, S., Chen, H., Ma, Z., Huang, C., … & Zhou, C. (2023). KEYNOTE‐033: randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD‐L1‐positive, advanced NSCLC. International Journal of Cancer, 153(3), 623-634.
9. Plimack, E. R., Powles, T., Stus, V., Gafanov, R., Nosov, D., Waddell, T., … & Rini, B. I. (2023). Pembrolizumab Plus Axitinib Versus Sunitinib as First-Line Treatment of Advanced Renal Cell Carcinoma: 43-Month Follow-up of the Phase 3 KEYNOTE-426 Study. European Urology, 84(5), 449-454.
10. Plimack, E. R., Powles, T., Stus, V., Gafanov, R., Nosov, D., Waddell, T., … & Rini, B. I. (2023). Corrigendum to” Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study”[Eur. (2023)]. European urology, 84(5), e123-e124.

11. Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur. Urol. (2023)] Primack, Elizabeth R. et al. European Urology, Volume 84, Issue 5, e123 – e124 

12. Felip E, Altorki N, Zhou C, Vallières E, Csoszi T, Vynnychenko IO, Goloborodko O, Rittmeyer A, Reck M, Martinez-Marti A, Kenmotsu H, Chen YM, Chella A, Sugawara S, Fu C, Ballinger M, Deng Y, Srivastava MK, Bennett E, Gitlitz BJ, Wakelee HA; IMpower010 Study

13. Investigators. Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial. J Clin Oncol. 2025 Jul 20;43(21):2343-2349. doi: 10.1200/JCO-24-01681. 

14. Kostiuchenko, V., Vynnychenko, I., Moskalenko, Y., & Pohorila, V. (2025). Detection of postoperative recurrence in colorectal cancer: Exploring the value of liquid biopsy. Regulatory Mechanisms in Biosystems, 16(1), e25020. https://doi.org/10.15421/0225020

15. Rini BI, Plimack ER, Stus V, Gafanov R, Waddell T, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, de Azevedo SJ, Borchiellini D, McDermott RS, Bedke J, Tamada S, Wu S, Markensohn J, Zhang Y, Loboda A, Vajdi A, Perini RF, Burgents J, Powles T. Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial. Nat Med. 2025 Aug 1. doi: 10.1038/s41591-025-03867-5. 

Scopus Author ID: https://www.scopus.com/authid/detail.uri?authorId= 57193309806

h-index: 4

ORCID ID: https://orcid.org/0000-0002-5398-0298

Research ID: ABG-1458-2020

Google Scholar: https://scholar.google.com.ua/citations?hl=uk&user=8tetJHcAAAAJ

Research Gate: https://www.researchgate.net/profile/Yuliia-Moskalenko-2

1. The role of PIK3CA mutations in the development of breast cancer (a literature review) / A.O. Pryvalova, I.O. Vynnychenko, V.Yu. Harbuzova, O.I. Vynnychenko, Yu.V. Moskalenko // Zaporozhye medical journal. – 2020. – V. 22, №4(121). – С. 554-560. https://doi.org/10.14739/2310-1210.2020.4.208402
2. Targeted therapy for non-small cell lung cancer focus on EGFR oncogenic mutation (literature review)/O. M. Smorodska, Yu. V. Moskalenko, I. O. Vynnychenko, O. I.[et al.] // Medicni perspektivi.- 2021 – Т. 26, № 2.- p. 8-11.
3. Smorodska O, Moskalenko Y, Vynnychenko I, Vynnychenko O, Kostuchenko V. Modern vector in treatment of patients with lung cancer: tyrosine kinase inhibitors in epidermal growth factor receptor mutations (literature review). Med. perspekt. [Internet]. 2021Jun.18 [cited 2021Sep.20];26(2):4-11. Available from: http://journals.uran.ua/index.php/2307-0404/article/view/234379
4. Piddubnyi, A., Kolomiiets, O., Danilchenko, S., Stepanenko, A., Moskalenko, Y., & Moskalenko, R. (2023). The Prospects of Using Structural Phase Analysis of Microcalcifications in Breast Cancer Diagnostics. Diagnostics, 13(4), 737.

5. Moskalenko, Y. (2024). Biological mechanisms of resistance to immune checkpoint inhibitors and overcoming this resistance: Challenges in medical oncology. Regulatory Mechanisms in Biosystems, 15(1), 83-91. https://doi.org/10.15421/022412.

6.  Vynnychenko OI, Lakhtaryna RY, Moskalenko YV. Breast cancer in Ukraine during the last decade. Світ медицини та біології.
   2024; 90(4): 30–33. doi: 10.26724/2079-8334-2024-4-90-30-33. 
7. Vynnychenko O, Moskalenko R. Biological mechanisms of resistance to trastuzumab and ways to overcome them: Modern problems of clinical oncology. Regulatory Mechanisms in Biosystems. 2024; 15(2): 345–352. doi: 10.15421/022449. 
8. Vynnychenko O, Moskalenko Y, Yazykov O, Tymchenko I, Seleznov O, Sulaieva O, Moskalenko R. Prognostic role of STAT6 in patients with non-small cell lung cancer. Regulatory Mechanisms in Biosystems. 2024; 15(4): 868–874. doi: 10.15421/0224125. 
9. Vynnychenko O, Moskalenko Y, Moskalenko R. Markers of inflammation as predictors of efficacy of trastuzumab therapy in HER2-positive metastatic breast cancer patients. Regulatory Mechanisms in Biosystems. 2025; 16(1): e25003. doi:10.15421/0225003. 
10. Vynnychenko OІ, Moskalenko YuV, Piddubnyi AM, Moskalenko RA. Distribution of M1 and M2 macrophages and their impact on survival in non-small cell lung cancer. Reports of Morphology. 2025; 31(1): 37–44. doi: 10.31393/morphology-journal-2025-31(1)-05. 
11. Moskalenko Y., Kravets O., Kovchun V. Clinical outcomes of concurrent use of corticosteroids and immune checkpoint inhibitors in oncology. Regul Mech Biosyst. 2025;16(2):e25062 doi: 10.15421/0225062 
12. Moskalenko Y, Kovchun V, Bohdanov A, Budko V, Yazykov O. Visceral Adipose Tissue Radiodensity as a Potential Biomarker of Immunotherapy Efficacy in Metastatic Non-Small Cell Lung Cancer Patients. Galician med. j. 2025;32(3):e-GMJ2025-A21. доступний у: https://doi.org/10.21802/e-GMJ2025-A21. 
13. Moskalenko Y, Yazykov O, Vasylieva O, Smiian K, Ivakhniuk T, Budko H, Moskalenko R. The Impact of Age on the Effectiveness of Immune Checkpoint Inhibitors Therapy in Patients with Metastatic Non-Small-Cell Lung Cancer. Geriatrics (Basel). 2025 Jun 27;10(4):85. doi:
    10.3390/geriatrics10040085. 
14. Kostiuchenko, V., Vynnychenko, I., Moskalenko, Y., & Pohorila, V. (2025). Detection of postoperative recurrence in colorectal cancer: Exploring the value of liquid biopsy. Regulatory Mechanisms in Biosystems, 16(1), e25020. https://doi.org/10.15421/0225020 
15. Kozakov D, Kobyliak N, Livshun S, Seleznov O, Koshyk O, Matvieieva A, Shparyk Y, Kolesnik O, Moskalenko Y, Vynnychenko O, Moskalenko R, Kropyvko S, Khmel A, Shkarupii B, Sulaieva O. Genetic alterations affect immune contexture of non-small cell lung cancer: Ukrainian study. Front Med (Lausanne). 2025 Jul 30;12:1558016. doi: 10.3389/fmed.2025.1558016. 

https://orcid.org/0009-0001-8017-788X

https://www.researchgate.net/profile/Ruslana–Lakhtaryna

https://scholar.google.com/citations?view_op=metrics_intro&hl=uk

1.  Liubchak, V. V., Khomenko, L. M., Kovalishyn, M. P., Ilina, V. V., Babar, T. V., & Sikora, V. V. (2021). New marketing tools in the blood service to optimize quality management.
2. Vynnychenko OI, Lakhtaryna RY, Moskalenko YV. Breast cancer in Ukraine during the last decade. Світ медицини та біології. 2024; 90(4): 30–33. doi: 10.26724/2079-8334-2024-4-90-30-33. 
3. Savchenko T, Lakhtaryna R, Denysenko A, Dovbysh A, Coupland SE, Moskalenko R. An Information-Extreme Algorithm for Universal
   Nuclear Feature-Driven Automated Classification of Breast Cancer Cells. Diagnostics (Basel). 2025 May 30;15(11):1389. doi: 10.3390/diagnostics15111389. 

Scopus Author ID: 57720919100

h-index: 1

ORCID ID: https://orcid.org/0000-0002-9577-0272

Google Scholar:https://scholar.google.com/citations?view_op=list_works&hl=uk&user=ouTGJgcAAAAJ

Research Gate:https://www.researchgate.net/profile/Kovchun-Viktor

1. Kachkovska V, Kovchun A, Kovchun V., Prystupa L.The role of Low-Dose CT scan in the early diagnosis of malignant neoplasms of different localization. European Respiratory Journal 2023, 62: PA5348. 
2. Moskalenko Y., Kravets O., Kovchun V. Clinical outcomes of concurrent use of corticosteroids and immune checkpoint inhibitors in oncology. Regul Mech Biosyst. 2025;16(2):e25062 doi: 10.15421/0225062 
3. Moskalenko Y, Kovchun V, Bohdanov A, Budko V, Yazykov O. Visceral Adipose Tissue Radiodensity as a Potential Biomarker of Immunotherapy Efficacy in Metastatic Non-Small Cell Lung Cancer Patients. Galician med. j. 2025;32(3):e-GMJ2025-A21. доступний у: https://doi.org/10.21802/e-GMJ2025-A21.